Trigonelline and sitagliptin attenuates nicotinamide-streptozotocin induced diabetic nephropathy in Wistar rats

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 5, Issue 4, 2013, Pages 583-589

  Kamble, Hemant V ^a   Bodhankar, Subhash L ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Diabetic nephropathy; Reactive oxygen species; Renal function test; Sitagliptin; Trigonelline

Indexed keywords

CREATININE; GLUCOSE; GLUTATHIONE; MALONALDEHYDE; NICOTINAMIDE; SITAGLIPTIN; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TRIGONELLINE; URIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; HISTOPATHOLOGY; KIDNEY MASS; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; UREA NITROGEN BLOOD LEVEL; URINE VOLUME;

EID: 84885342197     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Mclnnes AD. Diabetic foot disease in the United Kingdom: about time to put feet first. J Foot Ankle Res 2012; 5(26): 2-7.
2. Chan CN, Wingyee SR, Ronald CW, Peter CY, Rebecca W, Xilin Y. The complexity of vascular and non-vascular complications of diabetes: The Hong Kong diabetes registry. Curr Cardiovasc Risk Rep 2011; 5: 230-239.
3. Kouroumichakis I, Papanas N, Zarogoulidis P, Liakopoulos V, Maltezos E, Mikhailidis D. Fibrates: therapeutic potential for diabetic nephropathy. Eur J Intern Med 2012; 23: 309-316.
4. Mianzhi Z, Min X, Junbo G, Xiaoyue T. Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy. J Ethnopharmacol 2012; 141: 111-118.
5. Lin S, Yang J, Wu G, Liu M, Luan X, Lv Q, Zhao H, Hu J. Preventive effect of taurine on experimental type II diabetic nephropathy. J Biomed Sci 2010; 17(1): 3-8.
6. Freedman BI, Parekh RS, Kao L. Genetic basis of non-diabetic end-stage renal disease. Semin Nephrol 2010; 30(2): 101-110.
7. Cooper ME. Interaction of metabolic and hemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44(11): 1957-1972.
8. Somani R, Singhai A, Shivgunde P, Jain D. Asparagus racemosus wild (Liliaceae) ameliorates early diabetic nephropathy in STZ induced diabetic rats. Indian J Exp Biol 2012; 50: 469-475.
9. Kafle D, Singh N, Singh S, Singh N, Bhargav V, Singh AK. Persistent hyperglycemia generating reactive oxygen species in renal cells, a probable cause of inflammation in type 2 diabetic nephropathy subjects. Biomed Res India 2012; 23 (4): 501-504.
10. Korish A, Sallam R. Change in renal angiotensin II in the response to caffeic acid phenethyle ester in diabetic rats and its implications on diabetic nephropathy. Bull Alex Fac Med 2007; 43(2): 429-436.
11. White JR. Dipeptidyl peptidase-IV inhibitors: pharmacological profile and clinical Use. Clin Diabetes 2008; 26(2): 53-57.
12. Sanusi H. Role of incretin on diabetes mellitus. Acta Med Indones 2009; 41(4): 205-212.
13. Kolika C, Doupis J. Incretin-Based Therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther 2012; 2(2): 101-121.
14. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β-cell function in db/db mice. Br J Pharmacol 2009; 157: 415-426.
15. Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, Butler AE, Butler PC. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes. Diabetes 2009; 58: 1604-1615.
16. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13(4): 366-373.
17. Johnson K, Schurr K. Sitagliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Med Insights: Therapeutics 2011; 3: 81-92.
18. Yanai H, Adachi H, Hamasaki H, Masui Y, Yoshikawa R, Moriyama S, Mishima S, Sako A. Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis. J Clin Med Res 2012; 4(4): 251-258.
19. Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP-4 inhibitors-from preclinical development to clinical research. Kidney Blood Press Res 2012; 36: 65-84.
20. Alter M, Kretschmer A, Websky KV, Tsuprykov O, Reichetzeder C, Simon A, Stach JP, Hocher B. Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab 2012; 58: 659-671.
21. Vaghsiya J, Sheth N, Bhalodia Y, Manek R. Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Reg Peptides 2011; 166: 48-54.
22. Cristina M, Lemos ET, Vala H, Fernandes R, Oliveria J, Teixeira F, Teixeira F, Reis F. Diabetic nephropathy amelioration by a low dose sitagliptin in an animal model of type 2 Diabetes (Zucker diabetic fatty Rat). Exp Diabetes Res 2011; 10: 1-12.
23. Zhou J, Zhou S, Zeng S. Experimental diabetes treated with trigonelline: effect on β cell and pancreatic oxidative parameters. Fundam Clin Pharmacol 2013; 27 (3): 279-287.
24. Hiroshi A. Metabolism of alkaloids in coffee plants. Braz J Plant Physiol 2006; 18(1): 1-8.
25. Zhou J, Chan L, Zhou S. Trigonelline: a plant alkaloid with therapeutic potential for diabetes and central nervous system disease. Curr Med Chem 2012; 19(21): 3523-3531.
26. Shah SN, Bodhankar SL, Bhonde R, Mohan V. Hypoglycemic Activity of the combination of active ingredients isolated from Trigonella foenumgraceum in alloxan induced diabetic mice. Pharmacologyonline 2006; 1: 65-82.
27. Sayed AA, Khalifa M, Abdel-Latif FF. Fenugreek attenuation of diabetic nephropathy in alloxan-diabetic rats: attenuation of diabetic nephropathy in rats. J Physiol Biochem 2012; 68(2): 263-269.
28. Arora S, Bodhankar SL, Mohan V, Thakurdesai PA. Effects of reconstructed composition of Trigonella foenumgraceum L. seeds in animal model of diabetic nephropathy with and without renal ischemia reperfusion in rats. Indian J Pharmacol 2012; 8: 321-332.
29. Ghule A, Jadhav S, Bodhankar S. Trigonelline ameliorates diabetic hypertensive nephropathy by suppression of oxidative stress in kidney and reduction in renal cell apoptosis and fibrosis in streptozotocin induced neonatal diabetic (nSTZ) rats. Int Immunopharmacol 2012; 14(4): 740-748.
30. Qi MY, Chen K, Liu HR, Su YH, Yu SQ. Protective effect of icariin on the early stage of experimental diabetic nephropathy induced by streptozotocin via modulating transforming growth factor β 1 and type IV collagen expression in rats. J Ethnopharmacol 2011; 138: 731-736.
31. Kakadiya J, Patel D, Shah N. Effect of hesperidin on renal complication in experimentally induced renal damage in diabetic Sprague dawley rats. J Eco Biotech 2010; 2: 45-50.
32. Misera HP, Fridocich. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for SOD. J Biol Chem 1972; 3170-3175.
33. Morgon MS, Depirre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochem Biophys Acta 1979; 582: 67-78.
34. Slater TF, Sawyer BC. The stimulatory effects of carbon tetrachloride and other halogenoalkanes or peroxidative reactions in rat liver fraction in vitro. Biochem J 1971; 123: 805-814.
35. Ntemka A, Iliadis F, Papanikolaou NA, Grekas D. Network-centric analysis of genetic predisposition in diabetic nephropathy. Hippokratia 2011; 15 (3): 232-237.
36. Idonije BO, Festus O, Oluba OM. Plasma glucose, creatinine and urea levels in Type 2 diabetic patient attending a Nigerian Teaching Hospital. Res J Med Sci 2011; 5(1): 1-3.
37. Li TH, Wu ZD, Davey AK, Wang J. Antihyperglycemic effects of baicalin on streptozotocin-nicotinamide induced diabetic rats. Phyto Res 2011; 25(2): 189-194.
38. Oguanobi NI, Chijioke CP, Ghasi S. Anti-diabetic effect of crude leaf extracts of Ocimum gratissimum in neonatal streptozotocin-induced Type-2 model diabetic rats. Int J Pharm Pharm Sci 2012; 4(5): 77-83.
39. Saini S, Sharma S. Antidiabetic effect of Helianthus annuus L., seeds in ethanolic extract in streptozotocin-nicotinamide induced type 2 diabetes mellitus. Int J Pharm Pharm Sci 2013; 5(2): 382-387.
40. Masiello P, Broca C, Gross R, Roye M, Manteghetti M; Hillaire D, Novelli M, Ribes G. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 1998; 47 (2): 224-229.
41. Francesco PS, Loreto G. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005; 16: S30-S33.
42. Yamabe N, Yokozawa T, Oya T, Mujo K. Therapeutic potential of (-) Epigallocatechin 3-O-Gallate on renal damage in diabetic nephropathy model rats. J Pharmacol Exp Ther 2006; 319 (1): 228-236.
43. Dijk AV, Lthof MR, Meeuse J, Elin SE, Heine RH, Vandam R. Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance. Diabetes Care 2009; 32(6): 1023-1025.
44. Yeom JA, Kim ES, Ham DS. Both sitagliptin analogue & pioglitazone preserve the β-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice. BMB Reports 2011; 44(11): 713-718.
45. Barik R, Jain S, Qwatra D, Joshi A, Tripathi GS, Goyal R. Antidiabetic activity of aqueous root extract of Ichnocarpus frutescens in streptozotocin-nicotinamide induced in type-II diabetes in rats. Indian J Pharmacol 2008; 40: 19-22.
46. Pierre W, Gildas AJ, Ulrich MC, Modeste WN, Benoit NT, Albert K. Hypoglycemic and hypolipidemic effects of Bersama engleriana leaves in nicotinamide/streptozotocin induced type 2 diabetic rats. BMC Complement Altern Med 2012; 12: 2-6.
47. Ruiz-Ortega M, Ruperez M, Esteban V, Lorenzo S, Mezzano S, Plara JJ, et al. Angiotensin II increases connective tissue growth factor in the kidney. Am J Pathol 2003; 163(5): 1937-1947.
48. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 2008; 74: 22-36.
49. Firdous MS, Paul S, Bag AK. Effect of Sechium edule on chemical induced kidney damage in experimental animals. Bangladesh J Pharmacol 2013; 8: 28-35.
50. Mustafa HZ, Javad H, Mohmoodi M, Gholamhossein H, Hashemi B, Mohammad HZ. The effects of Persian shallot extract on the levels of some blood biochemical parameters in streptozotocin-induced diabetic rats. Afr J Agric Res 2012; 7(22): 3308-3313.
51. Woodhouse S, Batten W, Hendrick H, Malek PA. The glomerular filtration rate: an important test for diagnosis, staging and treatment of chronic kidney disease. Lab Medicine 2005; 37(4): 244-246.
52. Li Q, Xiao Y, Gong H, Shen D, Zhu F, Wu Q, Chen H, Zhong H. Effect of puerarin on the expression of extracellular matrix in rats with streptozotocin-induced diabetic nephropathy. Natl Med J India 2009; 22 (1): 9-12.
53. Owolabi OJ, Omogbai EK. Co-administration of glibenclamide and amlodipine induces resistance to hyperglycemic treatment in streptozotocin induced adapted/non adapted diabetic Rats. Clin Exp Pharmacol 2011; 1(1): 2-7.
54. Matough FA, Budin SB, Hamid ZA, Alwahaibi N, Mohamed J. The role of oxidative stress and antioxidants in diabetic complications. SQU Med J 2012; 12(1): 5-18.
55. Sayed AA. Thymoquinone and proanthocyanidin attenuation of diabetic nephropathy in rats. Eur Rev Med Pharmacol Sci 2012; 16: 808-815.
56. Noeman SA, Hamooda HE, Baalash AA. Biochemical study of oxidative stress markers in the liver, kidney and heart of high fat diet induced obesity in rats. Diabetol Metab Syndr 2011; 3 (17): 2-8.
57. Yu T, Jhun BS, Yoon Y. High-glucose stimulation increases reactive oxygen species production through the calcium and mitogen-activated protein kinase-mediated activation of mitochondrial fission. Antioxid Redox Signal 2011; 14 (3): 425-437.
58. Krishan P, Chakkarwar VA. Diabetic nephropathy: aggressive involvement of oxidative stress. J Pharm Educ Res 2011; 2(1): 35-41.
59. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovascular Therapeutics 2012; 30: 49-59.
60. Cheng J, Wang F, Yu DF, Wu PF, Chen JG. The cytotoxic mechanism of malondialdehyde and protective effect of carnosine via protein cross-linking/mitochondrial dysfunction/reactive oxygen species/MAPK pathway in neurons. Euro J Pharmacol 2011; 650: 184-194.
61. Allegra M, Gentile C, Tesoriere L, Livrea MA. Protective effect of melatonin against cytotoxic actions of malondialdehyde: an in vitro study on human erythrocytes. J Pineal Res 2002; 32(3): 187-193.
62. Soria CL, Gomez MR, Olvera LG, Gonazaler RG, Pacheco IR, Corona MA, et al. Transcriptomic analysis in diabetic nephropathy of streptozotocin-induced diabetic rats. Int J Mol Sci 2011; 12: 8431-8448.
63. Kiran G, Nandini CD, Ramesh HP, Sallimath PV. Progression of early phase of diabetic nephropathy in STZ induced diabetic rats: evalution of various kidney-related parameters. Indian J Exp Biol 2012; 50: 133-140.